Reinke P, Fietze E, Ode-Hakim S, Prösch S, Lippert J, Ewert R, Volk H D
Medical Clinic V-Nephrology, Universitätsklinikum Charité, Berlin, Germany.
Lancet. 1994;344(8939-8940):1737-8. doi: 10.1016/s0140-6736(94)92887-8.
The role of cytomegalovirus infection in allograft injury is controversial. A subgroup of renal graft recipients who had histologically proven late-acute rejection did not respond to conventional anti-rejection therapy (80% graft loss within 1 year). These patients showed an expansion of memory-type CD8 peripheral-blood T cells that expressed interferon-gamma mRNA and an association with clinically symptomless cytomegalovirus infection (82% PCR positive, 42% antigenaemia). Antiviral therapy with ganciclovir resulted in stable improved graft function in 17 of 21 treated patients with cytomegalovirus-associated late-acute rejection. The results underline the clinical relevance of cytomegalovirus-related graft injury and offer a novel therapeutic approach.
巨细胞病毒感染在同种异体移植损伤中的作用存在争议。一组经组织学证实为迟发性急性排斥反应的肾移植受者对传统抗排斥治疗无反应(1年内移植肾丢失率达80%)。这些患者表现为表达干扰素-γ mRNA的记忆型CD8外周血T细胞扩增,且与无症状巨细胞病毒感染相关(82% PCR阳性,42%抗原血症)。21例接受更昔洛韦抗病毒治疗的巨细胞病毒相关迟发性急性排斥反应患者中,17例移植肾功能稳定改善。这些结果强调了巨细胞病毒相关移植损伤的临床相关性,并提供了一种新的治疗方法。